Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (351-360 of 445) with videos related to

Pageof 45
Sort By:
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesDoga C Gulhan, Vinay Viswanadham, Francesc Muyas, et al.
Science Signaling|June 18, 2020
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumorsPatrick D Bhola, Eman Ahmed, Jennifer L Guerriero, et al.
Frontiers in Oncology|March 12, 2021
Defining the Extracellular Matrix of RhabdomyosarcomaXiaolei Lian, J Steffan Bond, Narendra Bharathy, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|October 4, 2005
Do attending physicians, nurses, residents, and medical students agree on what constitutes medical student abuse?Paul E Ogden, Edward H Wu, Michael D Elnicki, et al.
Cancer|April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumorsMeghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
JAMA Network Open|January 5, 2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical TrialBrandon M Huffman, Atrayee Basu Mallick, Nora K Horick, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
Pageof 45

Showing results (351-360 of 445) with videos related to

Sort By:
Pageof 45
Future Oncology (London, England)|February 13, 2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring <i>NRG1</i> gene fusionsDong-Wan Kim, Alison M Schram, Antoine Hollebecque, et al.
The Oncologist|May 14, 2014
Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinomaBrian M Wolpin, Douglas A Rubinson, Xiaoxu Wang, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signaturesDoga C Gulhan, Vinay Viswanadham, Francesc Muyas, et al.
Science Signaling|June 18, 2020
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumorsPatrick D Bhola, Eman Ahmed, Jennifer L Guerriero, et al.
Frontiers in Oncology|March 12, 2021
Defining the Extracellular Matrix of RhabdomyosarcomaXiaolei Lian, J Steffan Bond, Narendra Bharathy, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|October 4, 2005
Do attending physicians, nurses, residents, and medical students agree on what constitutes medical student abuse?Paul E Ogden, Edward H Wu, Michael D Elnicki, et al.
Cancer|April 12, 2023
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumorsMeghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, et al.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
JAMA Network Open|January 5, 2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical TrialBrandon M Huffman, Atrayee Basu Mallick, Nora K Horick, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
Pageof 45